Company Overview
Curanex Pharmaceuticals Inc functions as a developmental stage pharmaceutical entity dedicated to discovering, developing, and commercializing botanical drugs designed to treat patients suffering from inflammatory diseases. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on scientific research and development to bring novel therapeutic agents like Phyto-N to market for conditions including ulcerative colitis, atopic dermatitis, and COVID-19. Regarding its scale, the company carries a market capitalization of $13.60M, while annual revenue and employee count are not publicly disclosed in the provided financial data. This limited market capitalization indicates that Curanex is a micro-cap entity with a relatively small equity value, suggesting that its business operations are currently in an early-stage phase where revenue generation and workforce expansion have not yet reached the levels typical of mature pharmaceutical corporations.
Financial Health
The financial statements show a Net Income (TTM) of $-435,034, with Free Cash Flow at $-504,457, while Revenue (TTM) and EBITDA are listed as N/A. The significant negative net income relative to the absence of reported revenue highlights a cost structure dominated by research and development expenses rather than operational profitability, which is characteristic of developmental stage biotechnology firms. The Free Cash Flow of $-504,457 indicates that the company is consuming cash reserves to fund its operations and development pipeline, meaning it currently lacks the internal financial flexibility to generate positive cash flow from its existing business activities. Analysis of the three provided margins reveals a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, indicating that the company has not yet achieved profitability at either the gross or operating level due to high early-stage costs exceeding all current revenues. The balance sheet compares total cash of $108,862 against total debt of $476,452, resulting in a Debt to Equity ratio of 155.99, which signifies a highly leveraged position where liabilities significantly exceed equity. Despite the debt load, the Current Ratio stands at 9.37, indicating that the company holds sufficient liquid assets relative to its short-term obligations to maintain short-term liquidity, although the high leverage ratio suggests potential refinancing risks if cash flows do not improve. Furthermore, the Return on Equity is -85.2% and the Return on Assets is -30.0%, revealing that management effectiveness in generating returns on shareholder capital and assets is currently negative, a common but risky metric for companies in the developmental stage that have not yet transitioned to profitable operations.
Valuation Assessment
The Trailing P/E Ratio and Forward P/E Ratio are both listed as N/A, which implies that traditional earnings-based valuation metrics cannot be applied due to the company's lack of positive earnings or consistent profitability. The Price to Book ratio is 36.92, indicating a substantial market premium over the company's book value, which often occurs with biotechnology firms where market participants price in potential future asset value or pipeline potential rather than current tangible assets. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA are also listed as N/A, suggesting that these standard comparative metrics are not currently available for assessing the company's value relative to its sales or enterprise earnings. The stock has traded within a range defined by a 52-Week High of $9.18 and a 52-Week Low of $0.28, meaning the current price sits significantly closer to the low end of this historical range given the lack of positive earnings to support a higher valuation multiple. The Beta value is listed as N/A, preventing a direct comparison of the stock's price volatility relative to the broader market, though the high price-to-book ratio and negative returns suggest that the stock price may be driven more by speculative factors than by fundamental market movements typical of large-cap equities.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) figures are both listed as N/A, indicating that there is insufficient historical data to calculate growth rates, which is typical for a company with minimal or no recent revenue history. Since the company does not pay dividends, the Dividend Yield and Payout Ratio are both N/A and 0.0% respectively, meaning the company reinvests all available earnings or capital into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability and dividend income, with the company relying entirely on external capital to fund its botanical drug development initiatives. Consequently, the growth profile relies on the successful commercialization of future products rather than current financial performance metrics.